Product Listing

VENTANA PD-L1 IHC portfolio

PD-L1_dual_images4OWP_2880x656_px_hero
PD-L1 predictive assay: Guiding immunotherapy decisions
Our fully automated PD-L1 solutions empower choices by identifying patients who are most likely to benefit from specific therapies. The VENTANA PD-L1 (SP142) Assay and the VENTANA PD-L1 (SP263) Assay generate reliable results that direct patients to multiple immunotherapies. We support pathologist with the tools to successfully implement these assays into their laboratory workflow and interpret them proficiently.
 
These assays are used to identify patients more likely to respond to immunotherapies or to determine PD-L1 status to inform physicians considering treatment options for cancer patients.

PD-L1 indications, therapies and approvals

View Full Table

PD-L1 indications, therapies and approvals

 

VENTANA PD-L1 (SP263) Assay

VENTANA PD-L1 (SP142) Assay

NSCLC IMFINZI CE-IVD TECENTRIQ CE-IVD, PMA
KEYTRUDA CE-IVD
OPDIVO CE-IVD
UC TISLELIZUMAB NMPA TECENTRIQ CE-IVD, PMA
TNBC     TECENTRIQ CE-IVD, PMA

PD-L1 IHC assays

PD-L1 SP142 slide and therapy image

VENTANA PD-L1 (SP142) Assay (FDA approved)

Learn More
PD-L1 SP142 slide and therapy image

VENTANA PD-L1 (SP142) Assay (CE-IVD)

Learn More
PD-L1 SP263 slide and therapy image

VENTANA PD-L1 (SP263) Assay (CE-IVD)

Learn More

About PD-L1

Tumor microenvironment
Roche PD-L1 tumor microenvironment image
Immunologic checkpoint
Roche PD-L1 immunological checkpoint image
Interpretation training series
Roche pathology lab e-learning modules animation
Found 0 results in
Filters
...
    ...